Why Consolidated Edison, Newmont Mining, and Alexion Pharmaceuticals Are Today's 3 Worst Stocks

From utilities to commodities to health care, these 3 stocks all underperformed the stock market Wednesday

Mar 19, 2014 at 7:38PM
Longview

Over the past few weeks, Russian President Vladimir Putin proved to the world that he has the power to roil global markets, erase decades of diplomatic progress with the West, and begin to ruin Russia's economy all by himself. Few individuals wield more influence right now than the Russian leader, but Janet Yellen, head of the Federal Reserve, is one of them. And Yellen's remarks on Wednesday, which hinted at interest rates rising sooner than expected, sparked an immediate reaction on Wall Street. Seven in 10 stocks fell, and Consolidated Edison (NYSE:ED), Newmont Mining (NYSE:NEM), and Alexion Pharmaceuticals, (NASDAQ:ALXN) finished as the worst performers in the S&P 500 Index (SNPINDEX:^GSPC), which lost 11 points, or 0.6%, to end at 1,860.

Shares of Consolidated Edison, a diversified utilities company in the Northeastern U.S., lost 3.2% in the stock market today. Investors can take solace in the fact that utilities almost always have a rough time when interest rates rise, as they did today. That's because people who invest in utilities tend to be conservative, and often are primarily lured by the high dividends (Consolidated Edison pays a 4.6% annual dividend). When interest rates rise or are expected to rise, so do bond yields, providing an attractive alternative to dividend stocks. 

Newmont Mining, which produces gold, copper, and silver, saw shares shed 3.1% on Wall Street today. Two of those three commodities fell today, including the price of Newmont's specialty, gold. Again, Yellen showed her unique ability to influence the universe of investments, as her pre-emptive efforts to curb inflation by raising rates made gold, an inflation hedge, less attractive. With a longer-term view in mind, China's gradually slowing economy is a huge concern for Newmont Mining, and much of the company's fate rests in the hands of Chinese demand. 

Finally, shares of Alexion Pharmaceuticals, dipped 2.8% in trading today. The only predicate for the sell-off was the sorry state of the stock market at large Wednesday, and perhaps the fact that Alexion has soared to meteoric heights in recent times. It's nothing less than a one-way gain-train for investors wise enough to invest in the company a few years ago. From 2009 to 2013 Alexion's sales rocketed from about $380 million annually to over $1.5 billion per year, all on the success of Soliris, a genetic blood disorder. Soliris stands alone at the time being, facing no competition in its treatment area now, but this lack of competition could also be sending the stock to heady levels, so, as always, caveat emptor.

2 game-changing biotechs revolutionizing the way we treat cancer
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

John Divine has no position in any stocks mentioned. You can follow him on Twitter, @divinebizkid, and on Motley Fool CAPS, @TMFDivine.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers